



Tibor Zwimpfer

Switzerland

I bring to the ENYGO Executive Group a strong combination of clinical expertise, translational research leadership, and proven commitment to ESGO and ENYGO activities.

As a consultant and gynaecological oncology fellow at the University Hospital Basel and postdoctoral research fellow at the University of Basel, complemented by my role as Honorary Clinician Scientist at the Peter MacCallum Cancer Centre, I have developed a clinician-scientist profile deeply aligned with ESGO's mission to advance evidence-based care and improve outcomes for women with gynaecological cancers.

My research focuses on integrating multi-omic profiling with clinical data to understand treatment response in high-grade serous ovarian cancer, supported by over 1M EURO in competitive funding and multiple awards, including the 2025 HEMMI and SGGG-Bayer Prizes.

My active involvement across ESGO, including the Ovarian Cancer Database and Guidelines Working Groups, the ESGO EDI Committee, TransLink, Central Grants Office, and Awards/Survey Working Groups, demonstrates my long-standing engagement and collaborative mindset. As Vice-Chair of the ENYGO Scientific Committee and an active member of ENGOT, I help to shape scientific priorities, coordinated multicentre projects, and strengthened opportunities for young gynaecologic oncologists. Regular participation in ENYGO and ESGO committee meetings further underscores my commitment.

I am motivated to contribute strategic thinking, scientific rigor, and inclusive leadership to the Executive Group. With experience spanning international research consortia, clinical trials, biobanking, and guideline development, I aim to foster collaboration, empower early-career colleagues, and promote excellence and equity across the ENYGO community.

Curriculum vitae

PD Dr. Tibor Andrea Zwimpfer is a Swiss clinician-scientist in gynaecological oncology whose career integrates advanced surgical training, translational cancer research, and international collaborative leadership.

He completed his medical degree and MD at the University of Basel and is a Swiss-board-certified specialist in Obstetrics and Gynaecology.

In 2025, he achieved his Venia docendi (Dr. habil) at the University of Basel, reflecting his academic independence and sustained contributions to the field. Dr. Zwimpfer currently serves as Consultant and Gynaecological Oncology Fellow at the University Hospital Basel and as Postdoctoral Research Fellow in the Department of Biomedicine at the University of Basel.

He also holds an appointment as Honorary Clinician Scientist at the Peter MacCallum Cancer Centre in Melbourne. His earlier training includes clinical positions at the University Hospital Basel and the District Hospital Olten, complemented by research associate roles in anatomy and general surgery.

His teaching portfolio includes university lectureships, laparoscopic training, GESEA (Gynaecological Endoscopic Surgical Education and Assessment) tutoring, and supervision of multiple MD and master's theses. His research program focuses on high-grade serous ovarian cancer, specialising in the integration of multi-omic data with clinical outcomes to uncover molecular drivers of treatment response, homologous recombination deficiency, and poor survival.

During a two-year postdoctoral fellowship at the Peter MacCallum Cancer Centre under Professor David Bowtell, he applied integrative genomic and proteomic approaches to BRCA-mutated and homologous recombination proficient tumours, contributing to the Ovarian Tumour Tissue Analysis (OTTA) consortium, the Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG), and ESGO's international ovarian cancer research efforts. His recent work includes studies on homologous recombination deficiency associated survival, prognostic biomarkers, molecular characteristics of exceptional responders, and precision oncology strategies.

Dr. Zwimpfer has secured over 1 million CHF in competitive research funding as Principal Investigator, including Swiss National Science Foundation (SNSF) grants, support from the HOLCIM Foundation, the Cancer League of Basel, the SGGG-Bayer Grant, and several other foundations.

His distinctions include the 2025 HEMMI Prize, multiple Swiss Society of Gynaecology and Obstetrics (SGGG) scientific prizes, a winning proposal at ESGO's Ovarian Cancer Database initiative, and an award at the ENGOT GCA (Gynecologic Cancer Academy) workshop. He has contributed to major clinical and translational trials, including MATAO

(NCT04111978), Tumor Profiler (NCT06599749), and OV-Precision (NCT06466382), and serves as Swiss Principal Investigator in several ENGOT/NOGGO studies.

He also integrated the Basel Ovarian Biobank, a high-quality, prospectively maintained registry, into the OTTA consortium, enabling international harmonisation of biospecimen-based ovarian cancer research.

Dr. Zwimpfer has further strengthened his leadership through participation in professional development programs, including the Young Oncology Academy of the Swiss Group for Clinical Cancer Research (SAKK), the Gynecologic Cancer InterGroup (GCIg), and the ENGOT/GCA Young Investigator Program.

He serves as Vice-Chair of the ENYGO Scientific Committee and contributes to multiple ESGO Scientific Committee Working Groups. He is also a member of the ESGO Ovarian Cancer Guidelines update group and the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften) S2k guideline project on vaginal cancer.

Across his clinical, scientific, and organisational roles, Dr. Zwimpfer has developed a distinctive profile at the intersection of translational research, precision oncology, surgical practice, and European collaborative leadership, with the overarching aim of improving outcomes for women with gynaecological cancers.

PUBLICATION LIST TIBOR ZWIMPFER

<https://orcid.org/0000-0002-1574-6572>

<https://scholar.google.com/citations?user=6rmLtmwAAAAJ&hl=de>

Impact Factor (IF) and IF ranking according to Clarivate Journal Citation Reports 2025

Peer-reviewed Original Articles

1. **Zwimpfer TA**, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, Kennedy CJ, Bolithon A, Meagher NS, Milne K, Hamilton P, Alsop J, Antoniou AC, Au-Yeung G, Beckmann MW, Berrington de Gonzalez A, Bisinotto C, Blome F, Bodelon C, Boros J, Brand AH, Carney ME, Cazorla-Jiménez A, Chiu DS, Christie EL, Chudecka-Głaz A, Coulson P, Cushing-Haugen KL, Cybulski C, Darcy KM, David C, Davidson T, Ekici AB, Elishaev E, Emons J, Engler T, Farrell R, Fischer A, García-Closas M, Gentry-Maharaj A, Ghatage P, Glasspool R, Harter P, Hartkopf AD, Hartmann A, Heikau S, Hernandez BY, Hettiaratchi A, Heublein S, Huntsman DG, Jimenez-Linan M, Jones ME, Kang E, Kaznowska E, Kluz T, Kommoss FKF, Konecny G, Kruitwagen RFP, Kwon J, Lambrechts D, Lee CH, Lester J, Leung SCY, Leung Y, Linder A, Lissowska J, Loverix L, Lubiński J, Mateoiu C, McNeish IA, Moubarak M, Nelson GS, Nevins N, Olawaiye AB, Olbrecht S, Orsulic S, Osorio A, Quinn CM, Mohan GR, Ray-Coquard I, Rodríguez-Antona C, Roxburgh P, Ruebner M, Salfinger SG, Samra S, Schoemaker MJ, Sinn HP, Sonke GS, Steele L, Stewart CJR, Talhouk A, Tan A, Tarney CM, Taylor SE, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van Wageningen L, Wahner-Hendrickson AE, Walter C, Wang C, Welz J, Wentzensen N, Wilkens LR, Winham SJ, Winterhoff B, Anglesio MS, Berchuck A, Candido Dos Reis FJ, Cohen PA, Conrads TP, Crowe P, Doherty JA, Fasching PA, Fortner RT, García MJ, Gayther SA, Goodman MT, Gronwald J, Harris HR, Heitz F, Horlings HM, Karlan BY, Kelemen LE, Maxwell GL, Menon U, Modugno F, Neuhausen SL, Schildkraut JM, Staebler A, Sundfeldt K, Swerdlow AJ, Vergote I, Wu AH, Brenton JD, Pharoah PDP, Pearce CL, Pike MC, Goode EL, Ramus SJ, Köbel M, Nelson BH, DeFazio A, Friedlander ML, Bowtell DDL, Garsed DW. Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma. medRxiv [Preprint]. 2025 Sep 22:2025.09.17.25335919. <https://doi.org/10.1101/2025.09.17.25335919> (under review *Nat Commun*)
2. Heidinger M, **Zwimpfer TA**, Halbeisen FS, Maggi N, Frevert ML, Kiblawi R, Loesch JM, Schwab F, Kurzeder C, Montagna G, Weber WP. Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes. *Breast*. <https://doi.org/10.1016/j.breast.2025.104641>
IF 7.9, Ranking 4/141 Obstetrics & Gynecology (Q1), 40/328 Oncology (Q1)
3. Psilopatis I, Monod C, Filippi V, Tschudin R, Lapaire O, Emons J, Mosimann B, **Zwimpfer TA**. A comparative evaluation of publicly available large language models in the assessment of CTG traces according to the FIGO criteria. *Arch Gynecol Obstet*. 2025 Aug 21. <https://doi.org/10.1007/s00404-025-08145-w>
IF 2.5, Ranking 37/141 Obstetrics & Gynecology (Q2)
4. **Zwimpfer TA**, Heidinger M, Coelho R, Stiegeler N, Schwab FD, Montavon C, Eller RS, Maggi N, Loesch JM, Vetter M, Lambertini M, Weber WP, Kurzeder C, Heinzelmann-Schwarz V. TP53 Mutations and Phosphatidylinositol 3-Kinase/AKT Pathway Alterations Are Key Determinants of Breast Cancer Outcome Independent of Subtype and Stage. *JCO Precis Oncol*. 2025 May;9:e2400767. <https://doi.org/10.1200/PO-24-00767>
IF 5.8, Ranking 56/328 Oncology (Q1)
5. Geissler F, Graf F, **Zwimpfer TA**, Eller RS, Nguyen-Sträuli BD, Schötzau A, Heinzelmann-Schwarz V, Gobrecht-Keller U. Endocrine Maintenance Therapy in High-Grade Serous Ovarian Cancer: A Retrospective Off-Label Real-World Cohort Study. *Cancers (Basel)*. 2025 Apr 12;17(8):1301. <https://doi.org/10.3390/cancers17081301>
IF 4.4, Ranking 85/328 Oncology (Q2)

PUBLICATION LIST TIBOR ZWIMPFER

6. Heidinger M, Bilfeld G, Föge N, Loesch JM, Maggi N, Kiblawi R, Eller RS, Frevert ML, Schwab FD, Kurzeder C, **Zwimpfer TA***, Weber WP*. Association of immediate symmetrizing oncoplastic surgery with patient-reported outcomes in patients with breast cancer - A retrospective cohort study. *Am J Surg.* 2025 Mar 4;243:116286. <https://doi.org/10.1016/j.amjsurg.2025.116286>
IF 2.7, Ranking 64/314 Surgery (Q1)
7. Kacperczyk-Bartnik J, Khoptiana O, Žak K, Rajtak A, Shushkevich A, Pletnev A, Razumova Z, Strojna A, Bilir E, El Hajj H, **Zwimpfer TA**, Theofanakis C, Zalewski K, Bizzarri N, Bobiński M. Health care organization for gynecologic oncology patients fleeing Ukraine: Insights from the European Network of Young Gyne Oncologists survey during the first six months of the military conflict. *Int J Gynecol Cancer.* 2025 Feb 15:101719. <https://doi.org/10.1016/j.ijgc.2025.101719>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
8. Chacon E, El Hajj H, Hsu HC, Bizzarri N, Tsibulak I, Collins A, Cokan A, **Zwimpfer TA**, Strojna AN, Angeles MA, Kacperczyk-Bartnik J, Kahramanoglu I, Mínguez JÁ, Chiva L, Ramirez PT. Global practice patterns of sentinel lymph node biopsy in endometrial cancer: a survey from the European Network of Young Gynecologic Oncologists (ENYGO). *Int J Gynecol Cancer.* 2024 Dec 22:100068. <https://doi.org/10.1016/j.ijgc.2024.100068>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
9. Tsibulak I, Collins A, Hsu HC, Chacon E, Bizzarri N, Baleka AM, Razumova Z, Theofanakis C, Kacperczyk-Bartnik J, Strojna AN, Pletnev A, Angeles MA, Shushkevich A, Nikolova T, **Zwimpfer TA**, El Hajj H, Gaba F, Lanner M, Bilir E, Tóth R, Cokan A, Garcia J, Frumovitz M, Ramirez PT. Global survey on training and practice in sentinel lymph node mapping for endometrial and cervical cancer among early-career gynecologic oncologists. *Int J Gynecol Cancer.* 2025 Feb;35(2):100050. <https://doi.org/10.1016/j.ijgc.2024.100050>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
10. Saner FAM, Takahashi K, Budden T, Pandey A, Ariyaratne D, **Zwimpfer TA**, Meagher NS, Fereday S, Twomey L, Pishas KI, Hoang T, Bolithon A, Traficante N; Australian Ovarian Cancer Study Group; Alsop K, Christie EL, Kang EY, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Alsop J, Beckmann MW, Boros J, Brand AH, Brooks-Wilson A, Carney ME, Coulson P, Courtney-Brooks M, Cushing-Haugen KL, Cybulski C, El-Bahrawy MA, Elishaev E, Erber R, Gayther SA, Gentry-Maharaj A, Gilks CB, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Jakubowska A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Kluz T, Koziak JM, Kristjansdottir B, Le ND, Lener M, Lester J, Lubiński J, Mateoiu C, Orsulic S, Ruebner M, Schoemaker MJ, Shah M, Sharma R, Sherman ME, Shvetsov YB, Soong TR, Steed H, Sukumvanich P, Talhouk A, Taylor SE, Vierkant RA, Wang C, Widschwendter M, Wilkens LR, Winham SJ, Anglesio MS, Berchuck A, Brenton JD, Campbell I, Cook LS, Doherty JA, Fasching PA, Fortner RT, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sundfeldt K, Swerdlow AJ, Goode EL, DeFazio A, Köbel M, Ramus SJ, Bowtell DDL, Garsed DW. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma. *Clin Cancer Res.* 2024 Aug 15;30(16):3481-3498 <https://doi.org/10.1158/1078-0432.CCR-23-3552>
IF 10.2, Ranking 29/328 Oncology (Q1)
11. **Zwimpfer TA***, Bilir E*, Gasimli K, Cokan A, Bizzarri N, Razumova Z, Kacperczyk-Bartnik J, Nikolova T, Pletnev A, Kahramanoglu I, Shushkevich A, Strojna A, Theofanakis C, Cicakova T, Vetter M, Montavon C, Morgan G, Heinzelmann-Schwarz V. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO). *Cancers.* 2024 Mar 14;16(6):1155. <https://doi.org/10.3390/cancers16061155>
IF 4.4, Ranking 85/328 Oncology (Q2)

PUBLICATION LIST TIBOR ZWIMPFER

12. Förster CE, Calabretti I, Gubser L, Schötzau A, Fellmann-Fischer B, Heinzelmann-Schwarz V*, **Zwimpfer TA***. Comparison of different suture techniques for laparoscopic vaginal cuff closure. *Sci Rep.* 2024 Feb 28;14(1):4860. <https://doi.org/10.1038/s41598-024-55586-5>
IF 3.9, Ranking 25/136 Multidisciplinary Sciences (Q1)
13. Labrosse KB*, Marinho C*, Fellmann-Fischer B, Geissler F, Schötzau A, Heinzelmann-Schwarz V, **Zwimpfer TA**. Intracorporeal vs. extracorporeal open and closed knot tying techniques in laparoscopy: A randomized, controlled study. *Heliyon.* 2024 Jan 26;10(3):e25178. <https://doi.org/10.1016/j.heliyon.2024.e25178>
IF 3.6, Ranking 29/136 Multidisciplinary Sciences (Q1)
14. **Zwimpfer TA**, Scherer K, Schötzau A, Heinzelmann-Schwarz V, Hartmann K, Vetter M, Montavon C. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers. *Cancer Med.* 2023 Dec 22;13(1):e6840. <https://doi.org/10.1002/cam4.6840>
IF 3.1, Ranking 142/328 Oncology (Q2)
15. Wopen H, Keller M, Zocholl D, Mittelstadt S, Barretina-Ginesta MP, Heinzelmann-Schwarz V, Lafleur J, Kocián R, Baum J, Krabisch P, Achimas-Cadariu P, Vardar MA, Vergote I, Nasser S, Link T, Gil-Martin M, **Zwimpfer TA**, Leitner K, Jedryka M, Boxler T, Braicu EI, Sehoul J. Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey. *Cancers.* 2023 Nov 15;15(22):5428. <https://doi.org/10.3390/cancers15225428>
IF 4.4, Ranking 85/328 Oncology (Q2)
16. **Zwimpfer TA**, Wismer C, Fellmann-Fischer B, Geiger J, Schötzau A, Heinzelmann-Schwarz V. Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems using a pelvitrainer model: a randomized controlled study. *Updates Surg.* 2022 Jun;74(3):1137-1147. <https://doi.org/10.1007/s13304-021-01195-0>
IF 2.2, Ranking 95/314 Surgery (Q2)
17. **Zwimpfer T**, Lacher D, Fellmann-Fischer B, Mueller M. A laparoscopic study investigating 3D vs 2D imaging systems using a pelvitrainer model with experts, non experts, and students. *BMC Surg.* 9;20(1):276 (2020) <https://doi.org/10.1186/s12893-020-00892-8>
IF 1.8, Ranking 135/314 Surgery (Q2)
18. **Zwimpfer T**, Fellmann-Fischer B, Oehler R, Schötzau A, Kind A. A crossover study on the advantage of an additional rotation function in a needle holder compared to a conventional needle holder in a pelvitrainer model. *Laparasc Surg.* (2020) 4:10. [doi:10.21037/ls.2019.11.03](https://doi.org/10.21037/ls.2019.11.03)
IF 0.5, Ranking 395/495 Scimago Surgery
19. Hoechel S*, **Zwimpfer T***, Toranelli M, Müller-Gerbl M. The adaption of the bony-microstructure of the human glenoid cavity as result of the long- term biomechanical loading. *Surg Radiol Anat* 41:401-408 (2019) <https://doi.org/10.1007/s00276-019-02190-2>
IF 1.2, Ranking 163/212 Radiology, Nuclear Medicine & Medical Imaging (Q4), 14/22 Anatomy & Morphology (Q3)
20. Dell-Kuster S., Lauper S., Koehler J., Zwimpfer J., Altermatt B., **Zwimpfer T**, Zwimpfer L, Young J., Bucher HC, Nordmann AJ. Assessing work ability--a cross-sectional study of interrater agreement between disability claimants, treating physicians, and medical experts. *Scand J Work Environ Health.* 40(5):493-501. (2014) <https://doi.org/10.5271/sjweh.3440>
IF 4.3, Ranking 47/421 Public, Environmental & Occupational Health (Q1)

PUBLICATION LIST TIBOR ZWIMPFER

Peer-reviewed Review Articles

1. Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioulas-Siarkou C, Kacperczyk-Bartnik J, Bilir E, Chatzakis C, Caruso G, Bizzarri N, Dinas K, Bowtell DDL, Garsed DW, Ray-Coquard I, Ledermann JA, Friedlander M, Sotiropoulos A, Heinzlmann-Schwarz V, **Zwimpfer TA**. PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. *JAMA Netw Open*. 2025 Nov 3;8(11):e2541648. <https://doi.org/10.1001/jamanetworkopen.2025.41648>
IF 9.7, Ranking 16/332 Medicine, General & Internal (Q1)
2. Fotiou A, Margioulas-Siarkou C, Kacperczyk-Bartnik J, **Zwimpfer TA**, Dinas K, Petousis S. Fertility sparing treatment in patients with placental trophoblastic site tumor: a systematic review. *Int J Gynecol Cancer*. *Int J Gynecol Cancer*. 2025 June. <https://doi.org/10.1016/j.ijgc.2025.101972>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
3. Houssein EH, Kacperczyk-Bartnik J, Bizzarri N, Cokan A, Gasimli K, Nikolova T, Rosati A, Bilir E, **Zwimpfer TA**, Angeles MA, Strojna AN, Ghirardi V, Toth R, Viveros-Carreno D, Kahramanoglu I, Shushkevich A, Fagotti A, Ray-Coquard. Best original research presented at the 26th European Congress on Gynaecological Oncology: Best of ESGO 2025. *Int J Gynecol Cancer*. 2025 June. <https://doi.org/10.1016/j.ijgc.2025.101932>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
4. Kacperczyk-Bartnik J, El Hajj H, Tóth I, Bizzarri N, Tóth R, Razumova Z, **Zwimpfer TA**, Taumberger N, Bilir E, Strojna A, Angeles MA, Gasimli K, Nikolova T, Bartnik P, Cokan A, Sari SY, Kahramanoglu I, Caruso G, Joura EA, Kyrgiou M, Kesic V, Fagotti A, Arbyn M, Gultekin M. Declaration on cervical cancer elimination: literature review and perspectives from early-career clinicians. *Int J Gynecol Cancer*. 2025 Apr 26;35(7):101902. <https://doi.org/10.1016/j.ijgc.2025.101902>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
5. Kacperczyk-Bartnik J, El Hajj H, Bizzarri N, Bilir E, **Zwimpfer TA**, Strojna AN, Gasimli K, Angeles MA, Ghirardi V, Erfani H, Nikolova T, Theofanakis C, Tóth R, Ponce Sebastià J, Chiva L, Lorusso D. Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 2024. *Int J Gynecol Cancer*. 2024 Jul 20:ijgc-2024-005844. <https://doi.org/10.1136/ijgc-2024-005844>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
6. Stiegeler N, Garsed DW, Au-Yeung G, Bowtell DDL, Heinzlmann-Schwarz V, **Zwimpfer TA**. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: Treatment options for a poor prognosis group. *Front Onc*. 2024 Jun 4. <https://doi.org/10.3389/fonc.2024.1387281>
IF 3.3, Ranking 123/328 Oncology (Q2)
7. LiFE: Literature for ENYGO, Reviews covering publications from September 30, 2022–March 31, 2023. *Int J Gynecol Cancer*. 2024;34:1-34. <https://doi.org/10.1136/ijgc-34-S2>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
8. Kacperczyk-Bartnik J, Bizzarri N, **Zwimpfer TA**, El Hajj H, Angeles MA, Tóth R, Theofanakis C, Bilir E, Gasimli K, Strojna AN, Nikolova T, Ayhan A, Lorusso D, Chiva L. Best original research presented at the 24th European Congress on Gynaecological Oncology-Best of ESGO 2023. *Int J Gynecol Cancer*. 2023 Dec 7:ijgc-2023-005132. <https://doi.org/10.1136/ijgc-2023-005132>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
9. **Zwimpfer TA**, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzlmann-Schwarz V. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options. *Cancer Treat Rev*. 2023 Jan;112:102497. <https://doi.org/10.1016/j.ctrv.2022.102497>
IF 10.5, Ranking 28/328 Oncology (Q1)

PUBLICATION LIST TIBOR ZWIMPFER

Peer-reviewed Case Report Articles

1. **Zwimpfer TA**, Schwab FD, Steffens D, Kaul F, Schmidt N, Geiger J, Geissler F, Heinzelmann-Schwarz V, Weber WP, Kurzeder C. Contralateral lymph node metastasis in recurrent ipsilateral breast cancer with Lynch syndrome: a locoregional event. *World J Surg Oncol*. 2023 Feb 9;21(1):40. <https://doi.org/10.1186/s12957-023-02918-w>
IF 2.5, Ranking 70/314 Surgery (Q1), 188/328 Oncology (Q3)
2. **Zwimpfer T**, Monod C, Redling K, Willi H, Takes M, Fellmann-Fischer B, Manegold-Brauer G, Hösli I. Uterine pseudoaneurysm on the basis of deep infiltrating endometriosis during pregnancy- a case report. *BMC Pregnancy Childbirth*. 9;21(1):282. (2021) <https://doi.org/10.1186/s12884-021-03753-1>
IF 2.7, Ranking 31/141 Obstetrics & Gynecology (Q1)

Peer-reviewed Study Protocol Articles

1. **Zwimpfer TA**, Ewald H, Bilir E, Jayawardana M, Appenzeller-Herzog C, Bizzarri N, Razumova Z, Kacperczyk-Bartnik J, Heinzelmann-Schwarz V, Friedlander M, Bowtell DD, Garsed DW. Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma. *Cochrane Database Syst Rev*. 2024 Sep 23;9(9):CD015896. <https://doi.org/10.1002/14651858.CD015896>
IF 9.4, Ranking 17/332 Medicine, General & Internal Medicine (Q1)
2. **Zwimpfer TA**, Stiegeler N, Müller PC, Schötzau A, Fellmann-Fischer B, Heinzelmann-Schwarz V, Peterli R, Kraljević M. Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems in bariatric surgery: study protocol for a randomized controlled prospective trial. *Trials*. 2024 Feb 22;25(1):140. <https://doi.org/10.1186/s13063-024-07983-4>
IF 2.0, Ranking 125/195 Medicine, Research & Experimental (Q3)
3. McLaughlin PMJ, Klar M, **Zwimpfer TA**, Dutilh G, Vetter M, Marth C, du Bois A, Schade-Brittinger C, Reuss A, Bommer C, Kurzeder C, Heinzelmann-Schwarz V. Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. *BMC Cancer*. 2022 May 6;22(1):508. <https://doi.org/10.1186/s12885-022-09555-8>
IF 3.4, Ranking 118/328 Oncology (Q2)
4. Mujagic E*, **Zwimpfer T***, Marti WR, Zwahlen M, Hoffmann H, Kindler C, Fux C, Misteli H, Iselin L, Lugli AK, Nebiker CA, von Holzen U, Vinzens F, von Strauss M, Reck S, Kraljević M, Widmer AF, Oertli D, Rosenthal R, Weber WP. Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial. *Trials*. 24;15:188. (2014) <https://doi.org/10.1186/1745-6215-15-188>
IF 2.0, Ranking 125/195 Medicine, Research & Experimental (Q3)

Textbooks

1. **Zwimpfer TA**. Book chapters: Section II Vulvar Cancer, Metastatic; Section III Vaginal Cancer, Metastatic. Decision making in gynecologic oncology. Elsevier, accepted June 2024
2. **Zwimpfer TA**, Heinzelmann-Schwarz V. Skript G15 (Tumormarker in der Gynäkologie), EGONE gynécologie suisse
3. **Zwimpfer TA**, Heinzelmann-Schwarz V. Skript G14 (Malignome an Vulva und Vagina), EGONE gynécologie suisse
4. **Zwimpfer TA**, Heinzelmann-Schwarz V. Book chapter: Vaginal Cancer. Textbook of Gynaecological Oncology. 2023-09. *Part of* ISBN: [978-975-277-958-7](https://doi.org/10.1007/978-975-277-958-7)

Other Articles

1. **Zwimpfer TA**, Montavon C. Individualisierte Strategien für eine heterogene Patientinnengruppe Gynäkologische Tumore bei älteren Patientinnen. Schweizer Zeitschrift für Gynäkologie und Geburtshilfe. 2025-02.

PUBLICATION LIST TIBOR ZWIMPFER

<https://www.rosenfluh.ch/media/gynaekologie/2025/02/Individualisierte-Strategien-fuer-eine-heterogene-Patientinnengruppe-Gynaekologische-Tumore-bei-aelteren-Patientinnen.pdf>

2. **Zwimpfer TA**, Heinzelmann V. Management von Vulvakarzinomen. Vol. 13. 6_2023_info@gynäkologie, ISSN 1664-8382 <https://www.medinfo-verlag.ch/management-von-vulvakarzinomen/>
3. **Zwimpfer TA**, Heinzelmann V. Management of Vulvar Cancer. Vol. 13. 8_2023_info@ONCO-SUISSE <https://www.medinfo-verlag.ch/management-of-vulvar-cancer/>
4. **Zwimpfer TA**, Heinzelmann-Schwarz V. Tumormarker bei gynäkologischen Malignomen. Schweizer Zeitschrift für Gynäkologie und Geburtshilfe. 2023-10. <https://www.rosenfluh.ch/media/gynaekologie/2023/04/Tumormarker-bei-gynaekologischen-Malignomen.pdf>
5. **Zwimpfer TA**, Zaman K. ESMO 2020 Highlights: Gynecological Cancer. Leading Opinions, Hämatologie & Onkologie 08/2020

Conference papers in peer reviewed journals

1. Eller RS, Geissler F, Eberhardt A-L, **Zwimpfer TA**, Atila C, Nguyen BD, Heidinger M, Schwab F, Montavon C, Kurzeder C, Korach J, Tal O, Heinzelmann-Schwarz V. Revisiting radiotherapy: A forgotten ally in recurrent ovarian cancer treatment? A single-center retrospective cohort study. *Annals of Oncology*, Volume 36, S782. <https://doi.org/10.1016/j.annonc.2025.08.1837>
IF 65.4, Ranking 4/328 Oncology (Q1)
2. Chinczewski L, Kurtz JE, Saner F, Krajewska M, Leitner K, Barretina-Ginesta MP, Stanculeanu DL, Zikan M, Berek JS, Enzinger HM, Berton D, Mang C, Bernard T, Leseur J, **Zwimpfer TA**, Spranger A-L, Traut C, Denys C, Kretowska M, Sehouli J. Quality of life and lifestyle changes during and after therapy in women with endometrial cancer: A global study of 1,066 patients (NOGGO, ENGOT, GCIG, ENGAGe-IMPROVE/EXPRESSION XI). *JCO*. https://doi.org/10.1200/JCO.2025.43.16_suppl.5606
IF 43.4, Ranking 6/328 Oncology (Q1)
3. Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Kacperczyk-Bartnik J, Angeles MA, Bilir E, Caruso G, Friedlander M, Margioulas-Siarkou C, Sotiriadis A, Heinzelmann-Schwarz V, **Zwimpfer TA**. Efficacy and safety of PARP inhibitor maintenance in platinum-sensitive advanced-stage epithelial ovarian cancer: A systematic review and meta-analysis. *Int J Gynecol Cancer*. 2025;35(2):100336. <https://doi.org/10.1016/j.ijgc.2024.100336>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
4. El-Hajj H, Bilir E, Lambertini M, Petousis S, Sanchez-Bayona R, Kfoury M, Kacperczyk-Bartnik J, Angeles MA, Rosati A, Caruso G, Gasimli K, Razumova Z, Kahramanoglu I, Bizzarri N, Strojna AN, Amant F, Martinez A, Heinzelmann-Schwarz V, **Zwimpfer TA**. Current practices and barriers in HRD and BRCA testing for ovarian cancer: Preliminary findings from the ENYGO cross-sectional study. *Int J Gynecol Cancer*. 2025;35(2):101585. <https://doi.org/10.1016/j.ijgc.2024.101585>
IF 4.7, Ranking 77/326 Oncology (Q1), 8/140 Obstetrics & Gynecology (Q1)
5. Kacperczyk-Bartnik J, Arbyn M, Denoël S, Dhollander N, Razumova Z, Theofanakis C, Bilir E, Gasimli K, Cokan A, **Zwimpfer TA**, Kyrgiou M, Gultekin M, Bizzarri N. Attitudes and practice of gynaecologists regarding HPV vaccination of adolescents assessed in the ESGO-PERCH HPV survey. *Int J Gynecol Cancer*. 2025;35(2):101319. <https://doi.org/10.1016/j.ijgc.2024.101319>
IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)
6. Kacperczyk-Bartnik J, Arbyn M, Denoël S, Dhollander N, Razumova Z, Theofanakis C, Bilir E, Gasimli K, Cokan A, **Zwimpfer TA**, Kyrgiou M, Gultekin M, Bizzarri N. Prophylactic HPV vaccination in patients with gynaecologic cancer: Practices, challenges, and recommendations reported in the ESGO-PERCH HPV survey. *Int J Gynecol Cancer*. 2025;35(2):100378. <https://doi.org/10.1016/j.ijgc.2024.100378>

PUBLICATION LIST TIBOR ZWIMPFER

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

7. **Zwimpfer TA**, Coelho R, Au-Yeung G, Eller R, Pandey A, Fereday S, Twomey L, Ariyaratne D, Traficante N, Kennedy C, Goode EL, AOCs Study Group, OTTA Consortium, Defazio A, Heinzelmann-Schwarz V, Ramus SJ, Koebel M, Jacob F, Bowtell DDL, Garsed DW. Co-amplification of CCNE1 and AKT2 as prognostic biomarker and therapeutic target in tubo-ovarian high-grade serous carcinoma. *Int J Gynecol Cancer*. 2025;35(2):101684. <https://doi.org/10.1016/j.ijgc.2025.101684>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

8. Fotiou A, Margioulas-Siarkou C, **Zwimpfer TA**, Kacperczyk-Bartnik J, Dinas K, Petousis S. Fertility sparing treatment in patients with placental trophoblastic site tumor: A systematic review. *Int J Gynecol Cancer*. 2025;35(2):101498. <https://doi.org/10.1016/j.ijgc.2024.101498>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

9. Bilir E, **Zwimpfer TA**, Razumova Z, Tóth R, Ghirardi V, Kacperczyk-Bartnik J, Chacon E, Strojna AN, Fagotti A, Harter P, Oonk M, Classe JM, Van Driel WJ, Shi T, Plante M, Coleman RL, Ramirez PT, Bizzarri N. Challenges in surgical randomized controlled trials (RCTs) in gynaecologic oncology: Insights from a ENYGO study. *Int J Gynecol Cancer*. 2025;35(2):101710. <https://doi.org/10.1016/j.ijgc.2025.101710>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

10. Eller RS, Geissler F, Tal O, Eberhardt AL, **Zwimpfer TA**, Korach J, Heinzelmann-Schwarz V. Secondary debulking followed by localised radiotherapy in patients with oligometastatic recurrent ovarian cancer – A case series of two international cancer centres. *Int J Gynecol Cancer*. 2025;35(2):101143. <https://doi.org/10.1016/j.ijgc.2024.101143>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

11. Bilir E, El Hajj H, Gasimli K, Kacperczyk-Bartnik J, Bizzarri N, Kahramanoglu I, Razumova Z, **Zwimpfer TA**, Theofanakis C, Pletnev A, Shushkevich A, Strojna AN, Viveros-Carreño D, Segarra B, Agusti N. Motivators and barriers to exercise prescription in gynecologic oncology: Preliminary results from an ENYGO cross-sectional study. *Int J Gynecol Cancer*. 2025;35(2):100954. <https://doi.org/10.1016/j.ijgc.2024.100954>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

12. Bilir E, Zimmermann S, El-Hajj H, **Zwimpfer TA**, Kacperczyk-Bartnik J, Razumova Z, Kahramanoglu I, Bizzarri N, Theofanakis C, Pletnev A, Shushkevich A, Strojna AN, Gasimli K. Urinary incontinence management in patients with primary endometrial cancer: Preliminary results from the ENYGO cross-sectional study. *Int J Gynecol Cancer*. 2025;35(2):101347. <https://doi.org/10.1016/j.ijgc.2024.101347>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

13. Coelho R, Seashore-Ludlow B, Schütz S, Lombardo FC, Schmid V, Alflen L, **Zwimpfer TA**, Hensler M, Fedier A, Tumor Profiler Consortium, Fucikova J, Kallioniemi O, David L, Heinzelmann-Schwarz V, Jacob F. Tumor-associated macrophages improve the efficacy of SMAC mimetics combined with chemotherapy in ovarian cancer. *Int J Gynecol Cancer*. 2025;35(2):101462. <https://doi.org/10.1016/j.ijgc.2024.101462>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

14. **Zwimpfer TA**, Pandey A, Fereday S, Coelho R, Twomey L, Ariyaratne D, Traficante N, Jacob F, Eller R, Heinzelmann-Schwarz V, Christie EL, Kennedy C, Au-Yeung G, Ramus S, Koebel M, Nelson BH, Goode EL, Defazio A, Bowtell DDL, Garsed DW. Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival *Annals of Oncology*, (2024) <https://doi.org/10.1016/j.annonc.2024.08.813>.

IF 65.4, Ranking 4/328 Oncology (Q1)

15. **Zwimpfer TA**, Pandey A, Fereday S, Twomey L, Ariyaratne D, Goode EL, Nelson BH, Defazio A, Bowtell DDL, Garsed DW. Multi-omic and clinicopathological analysis of BRCA-altered tubo-ovarian high-grade serous carcinoma with exceptionally poor survival: identification of predictive biomarkers for personalized treatment. *Mol Oncol*, (2024) 18: 1-495. <https://doi.org/10.1002/1878-0261.13683>

PUBLICATION LIST TIBOR ZWIMPFER

IF 4.5, Ranking 84/328 Oncology (Q2)

16. **Zwimpfer TA**, Lombardo F, Rimmer N, Götze S, Singer F, Bertolini A, Montavon C, Kurzeder C, Jacob F, Heinzelmann-Schwarz V. Integrated multi-omic and clinicopathological analysis of vulvar squamous cell carcinoma: identification of predictive biomarkers for personalized treatment. *Int J Gynecol Cancer* 2023;**33**:A364. <http://dx.doi.org/10.1136/ijgc-2023-esgo.773>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

17. Chinczewski L, Krause C, Zocholl D, Boer J, Saner F, Liebrich C, Zob DL, **Zwimpfer T**, Kühn C, Rothmund R, Gheorghe AS, Ugur MC, Müller M, Klenske J, Heinzelmann-Schwarz V, Stahl N, Heubner M, Keller M, Sehouli J. Changes of lifestyle, exercise of precaution and preferences – interim results of an international survey for endometrial cancer patients (NOGGO, ENGOT, GCIG – expression XI/IMPROVE) *Int J Gynecol Cancer* 2023;**33**:A159-A160. <http://dx.doi.org/10.1136/ijgc-2023-esgo.328>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

18. **Zwimpfer TA**, Fereday S, Ariyaratne D, Twomey L, Traficante N, Goode EL, Defazio A, Bowtell DL, Garsed DW. Influence of predictive features on therapy response and survival in high-grade serous ovarian cancer patients by germline BRCA mutation status: an update from the australian ovarian cancer study. *Int J Gynecol Cancer* 2023;**33**:A36. <http://dx.doi.org/10.1136/ijgc-2023-esgo.56>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

19. **Zwimpfer TA**, Fereday S, Pandey A, Twomey L, Ariyaratne D, Nelson BH, Goode EL, Defazio A, Bowtell DL, Garsed DW. Integrated multi-omic and clinicopathological analysis of high-grade serous ovarian cancer in BRCA1/2 mutated patients with poor survival: identification of predictive biomarkers for personalized treatment. *Int J Gynecol Cancer* 2023;**33**:A32-A33. <http://dx.doi.org/10.1136/ijgc-2023-esgo.49>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

20. Chinczewski L, Krause C, Zocholl D, Boer J, **Zwimpfer T** et al. Patients with endometrial cancer: Expectations and preferences towards therapy and quality of life—First results of an international survey (NOGGO, ENGOT, GCIG - IMPROVE/EXPRESSION XI). *JCO* (2023), http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e24120

IF 4.3, Ranking 6/328 Oncology (Q1)

21. Lombardo F, **Zwimpfer T**, Rimmer N, Götze S, Bertolini A, Singer F, Kurzeder C, Jacob F, Heinzelmann-Schwarz V. Integrated multi-omic and clinicopathological analysis of vulvar squamous cell carcinoma: identification of predictive biomarkers for personalized treatment. *Mol Oncol*, (2023) <https://doi.org/10.1002/1878-0261.13471>

IF 4.5, Ranking 84/328 Oncology (Q2)

22. **Zwimpfer T**, Scherer K, Schötzau A, Heinzelmann-Schwarz V, Montavon C. Desensitization for platinum and taxane hypersensitivity in gynecological cancers - a retrospective study. (2022), Category – High Risk Pregnancy. *BJOG: Int J Obstet Gy*, 129: 42-43.

IF 4.3, Ranking 10/141 Obstetrics & Gynecology (Q1)

23. **Zwimpfer T**, Wismer C, Oehler R, Hasbargen K, Geiger J, Schötzau A, Fellmann B, Heinzelmann-Schwarz V. Evaluation of a game box for laparoscopic training: A randomized study (2022), Category – High Risk Pregnancy. *BJOG: Int J Obstet Gy*, 129: 205-205.

IF 4.3, Ranking 10/141 Obstetrics & Gynecology (Q1)

24. Geissler F, Coelho R, **Zwimpfer T**, Fedier A, Jacob F, Heinzelmann-Schwarz V. BCARE- functionally assessing treatment response in ovarian cancer patients. *Int J Gynecol Cancer* 2021;**31**:A107-A108. <https://10.1136/IJGC-2021-IGCS.268>

IF 4.7, Ranking 77/328 Oncology (Q1), 8/141 Obstetrics & Gynecology (Q1)

25. **Zwimpfer T**, Wismer C, Schötzau A, Fellmann-Fischer B, Heinzelmann-Schwarz V. A randomized study comparing 2D 4K and 3D 4K laparoscopic imaging systems. (2021), Category – High Risk Pregnancy. *BJOG: Int J Obstet Gy*, 128: 130-130.

PUBLICATION LIST TIBOR ZWIMPFER

IF 4.3, Ranking 10/141 Obstetrics & Gynecology (Q1)

26. **Zwimpfer T**, Monod C, Redling K, Willi H, Takes M, Fellmann-Fischer B, Manegold-Brauer G, Hösli I. Uterine pseudoaneurysm on the basis of deep infiltrating endometriosis during pregnancy. (2021), Category – High Risk Pregnancy. *BJOG: Int J Obstet Gy*, 128: 75-112. https://doi.org/10.1111/1471-0528.7_16715

IF 4.3, Ranking 10/141 Obstetrics & Gynecology (Q1)

27. **Zwimpfer T**, Geissler F, Rimmer N, Konantz M, Heinzelmann-Schwarz V, Jacob F. Real-time personalized drug prediction in ovarian cancer patients using zebrafish patient-derived xenografts to support clinical decision making. *BJOG* (2021), Category – Gynae Oncology. *BJOG: Int J Obstet Gy*, 128: 56-74. https://doi.org/10.1111/1471-0528.6_16715

IF 4.3, Ranking 10/141 Obstetrics & Gynecology (Q1)